PPARG and ASS1: Targets of Metabolic Alteration in Venetoclax / Decitabine Resistant Acute Myeloid Leukemia

The combination of venetoclax (VEN), an inhibitor of the anti-apoptotic factor BCL2, with the hypomethylating agent (HMA) decitabine (DEC) is the current frontline standard therapy for elderly patients with acute myeloid leukemia (AML). Despite the success of VEN/HMAs in inducing remission in AML, s...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2023-11, Vol.142 (Supplement 1), p.4162-4162
Hauptverfasser:	Yamatani, Kotoko, Watanabe, Tatsuro, Saito, Kaori, Maiti, Abhishek, Yamashita, Satoshi, Khasawneh, Abdullah, Paran, Faith Jessica, Hayes, Kala, Borthakur, Gautam, Harman, Joe R, Kimura, Shinya, DiNardo, Courtney D., Milne, Thomas A, Andreeff, Michael, Tabe, Yoko, Konopleva, Marina Y.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!